Royalty Pharma (RPRX) Current Assets (2019 - 2026)

Royalty Pharma has reported Current Assets for 8 years, with the latest figure at $1.4 billion in Q1 2026.

• Quarterly Current Assets fell 22.65% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 22.65% YoY) and the FY2025 annual result came in at $1.5 billion, down 15.21% from the prior year.
• Current Assets fell to $1.4 billion in Q1 2026 per RPRX's latest filing, from $1.5 billion in the prior quarter.
• Over five years, Current Assets peaked at $3.5 billion in Q2 2022 and troughed at $1.3 billion in Q4 2023.
• A 5-year average of $2.1 billion and a median of $1.8 billion in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets slumped 50.13% in 2023, then jumped 41.43% in 2024.
• Over 5 years, Current Assets stood at $2.6 billion in 2022, then plunged by 50.13% to $1.3 billion in 2023, then soared by 41.43% to $1.8 billion in 2024, then decreased by 15.21% to $1.5 billion in 2025, then declined by 6.69% to $1.4 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $1.4 billion, $1.5 billion, and $1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.